In a proof of principal approach, the therapeutic application of FAP inhibitors was demonstrated in a patient with metastasized breast cancer treated with 2.9 GBq 90Y-FAPI-04, which led to a reduction in pain medication at a considerably low dose [70]. This evidence concerns the gene FAP and breast cancer.